en · de · es
selank-notes.peptides3081.com › Info › Proposed Mechanisms And Research Endpoints — Deep Dive

Proposed Mechanisms And Research Endpoints — Deep Dive

By Editorial Desk · published 2025-08-13 · last reviewed 2025-09-02 · Info

The short version of elevated plus maze fits in a sentence. The long version — which is the one that helps — is below.

This page was last updated on 2025-09-02 and is reviewed periodically as new material appears.

Proposed Mechanisms and Research Endpoints

Selank is studied chiefly as an animal-model anxiolytic with proposed secondary effects on memory and immune signaling. Reported mechanisms include modulation of the GABA-A receptor complex, inhibition of enkephalin-degrading enzymes, and shifts in monoamine turnover within limbic structures. Some experiments describe increased expression of brain-derived neurotrophic factor in the hippocampus after repeated dosing. No single molecular target has been confirmed, and the peptide does not bind any receptor with the selectivity typical of a conventional small-molecule drug. Mechanism therefore remains a set of hypotheses rather than an established pathway.

Laboratory work relies on standard behavioral paradigms. Rodents are tested in the elevated plus maze, open field, and passive avoidance tasks, with outcomes compared against diazepam or vehicle controls. Intranasal dosing is used most often because it bypasses first-pass metabolism, though intraperitoneal and intravenous routes also appear in published protocols. Biochemical endpoints include tissue BDNF concentrations, cytokine levels, and monoamine metabolites. Human data are limited to small Russian trials reporting reduced anxiety scores; most were not prospectively registered, and few employed independent outcome assessment.

Analytical Methods and Material Handling

Lyophilized material is generally stable for extended periods when kept dry at or below minus twenty degrees Celsius. Working solutions are less stable, and common practice is to aliquot and freeze them so that repeated freeze-thaw cycles are avoided. Aqueous solutions are sensitive to pH extremes and to microbial growth, so short-term storage at refrigerator temperature is typical. Oxidation and hydrolysis are the principal degradation routes. Reconstitution with sterile water or a mild buffer is standard, and solutions should be protected from light.

Regulatory treatment varies by jurisdiction. In Russia the compound is a registered prescription product, while in the European Union and the United States it is generally handled as a research chemical without a marketing authorization. Suppliers therefore operate outside pharmaceutical oversight, and buyers rely on supplier documentation for purity and identity claims. Chain of custody and third-party testing are the main verification tools. Analysts note that the absence of a pharmacopoeial monograph for research-grade material limits standardization across vendors.

Purity assessment relies mainly on reverse-phase high-performance liquid chromatography with ultraviolet detection. Because the peptide lacks a strong chromophore, detection often uses backbone absorbance near 214 nm. Identity is confirmed by mass spectrometry, typically electrospray ionization or matrix-assisted laser desorption, comparing the measured mass against the expected value. Amino acid analysis can verify composition after acid hydrolysis. Diastereomer content and residual counterions are reported less often, although both can influence biological assays.

Selank at a glance

PropertyValueNotes
Principal proposed targetGABA-A receptor complexHypothesis derived mainly from animal pharmacology
Common behavioral assayElevated plus mazeRodent test for anxiety-like behavior
Reported molecular markerHippocampal BDNF expressionMeasured by immunoassay or mRNA quantification
Typical dosing routeIntranasalChosen to reduce first-pass metabolism
Reported plasma half-lifeMinutesBased on limited peptide stability data

Peptide Identity and Structure

Selank is a synthetic heptapeptide with the sequence Thr-Lys-Pro-Arg-Pro-Gly-Pro, written TKPRPGP in one-letter notation. Its structure consists of the immunomodulatory tetrapeptide tuftsin, Thr-Lys-Pro-Arg, extended at the carboxyl terminus by a Pro-Gly-Pro segment. The molecular formula is commonly given as C33H57N11O9, corresponding to a monoisotopic mass near 751.4 Da and an average molecular mass near 751.9 Da. All seven residues are proteinogenic amino acids, and the molecule carries no modified side chains or non-natural linkages.

The compound was designed at the Institute of Molecular Genetics of the Russian Academy of Sciences during the 1980s and 1990s. The stated design goal was to retain the immunomodulatory and central nervous system activity attributed to tuftsin while improving resistance to enzymatic breakdown. Adding a proline-rich tail to the short parent peptide was a deliberate strategy, because proline residues restrict the conformations available to many peptidases. The same laboratory produced Semax, an ACTH fragment analog, and both compounds were developed in parallel as short, enzymatically stabilized peptides intended for intranasal use.

Selank is not a naturally occurring peptide and has no known endogenous counterpart in human physiology. Russian-language sources frequently call it TP-7, while English-language sources use the name Selank almost exclusively. Database indexing is uneven, partly because early reports appeared in regional journals that are not widely cataloged. Some summaries describe the material as a tuftsin analog and others as a synthetic heptapeptide; the labels overlap rather than conflict. Citing the primary sequence resolves ambiguity more reliably than the research or trade name alone.

Related pages on this site

Mechanism and Evidence Base

Proposed mechanisms center on modulation of the GABA system, but no single molecular target has been confirmed. Rodent studies report changes in GABA-A receptor expression and in the turnover of serotonin, dopamine, and norepinephrine in several brain regions. Increases in brain-derived neurotrophic factor and its receptor have also been described after repeated administration. These findings come largely from animal models, and the degree to which they describe human neurochemistry remains an open question. The mechanism is best characterized as multi-system and not fully resolved.

Pharmacokinetic data are limited. Like most short peptides, Selank is vulnerable to plasma and tissue peptidases, and its measured half-life in circulation is short, on a minutes scale. The Pro-Gly-Pro tail slows this degradation but does not eliminate it. Intranasal administration is the route described in most reports, with absorption through the nasal mucosa and a hypothesized path into the central nervous system that avoids the blood-brain barrier. Direct measurements of human brain exposure are unavailable, so distribution claims rest on inference from animal work.

Clinical evidence comes mainly from small studies conducted in Russia, several of which were open-label or lacked robust blinding. Reported outcomes include lower anxiety scores, changes in attention measures, and effects on asthenic states following illness. Sample sizes are typically in the tens of participants, and independent replication outside the region is scarce. Reviews published in English generally note the limited methodological quality of the underlying trials. Whether the compound produces clinically meaningful effects under rigorous conditions remains unresolved.

Analytical Methods and Stability

Peptide bonds in selank are susceptible to hydrolysis under strongly acidic or basic conditions, and the terminal proline residues are vulnerable to exopeptidase activity in biological samples. Lyophilized powder stored dry at -20 °C typically remains stable for extended periods, whereas aqueous solutions degrade faster and may lose measurable purity within days to weeks depending on pH, temperature, and microbial load. Repeated freeze-thaw cycles promote aggregation and adsorption to container surfaces. For analytical work, solutions are usually prepared fresh, kept cold, and used within a single working day.

Handling follows standard practice for research peptides. Material is weighed in a low-humidity environment because the powder absorbs atmospheric moisture. Purity is reported as the percentage area of the main peak in a chromatogram, with specifications commonly set at 95 percent or higher; values below that threshold indicate the presence of truncated or modified species. Residual trifluoroacetate from purification is often present and may affect mass balance. Certificates of analysis should state the analytical method, the column and gradient used, and the lot-specific retention time so that results can be compared across suppliers.

Identity and Structural Background

Selank is a synthetic heptapeptide with the sequence Thr-Lys-Pro-Arg-Pro-Gly-Pro, frequently abbreviated as TKPRPGP. It was designed as a structural analogue of tuftsin, a naturally occurring tetrapeptide released by enzymatic cleavage of the immunoglobulin heavy chain. The two additional proline residues at the C-terminal end extend the parent chain and change how the molecule behaves in solution. The free peptide has a calculated molecular mass of approximately 751.9 g/mol and is generally supplied as a lyophilised white to off-white powder.

Development work on the compound began in the 1980s and 1990s at the Institute of Molecular Genetics in Moscow, within the same research programme that produced the peptide Semax. Early investigators sought a tuftsin derivative with improved resistance to enzymatic breakdown and with activity in the central nervous system after peripheral administration. Most of the primary literature from this period was published in Russian, a factor that still shapes how easily the findings can be checked by outside groups.

Naming for this compound is not fully standardised in English sources. The spelling Selanc appears in some transliterations, and catalogue entries may instead list the peptide sequence itself as the identifier. Reference material sometimes groups it with other short synthetic peptides studied for behavioural effects, which can create confusion when citations are compared. Distinguishing the exact sequence from related tuftsin analogues is therefore a practical first step when reviewing any dataset or specification sheet.

Reference notes

In September 2008, Aboitiz Equity Ventures decided to quit the shipping business to focus on its core businesses, namely power and financial services, and announced the sale of its controlling 77% stake in Aboitiz Transport System to KGLI‑NM Holdings, a joint venture between Negros Navigation and Dutch investors, with plans to acquire the remaining shares and potentially delist the company, but due to financing difficulties during the global financial crisis, KGLI‑NM was unable to complete the full buyout, paid only a P100 million option fee, and eventually withdrew its offer in May 2009, terminating the agreement. On December 1, 2010, Aboitiz Equity Ventures sold its transport business to Negros Navigation Co. Inc. (NENACO) for US$105 million, transferring all logistics and shipping operations under new ownership. At the same time, the China–ASEAN Investment Cooperation Fund, a Netherlands-based private equity firm owned by the Government of the People's Republic of China, acquired a controlling stake in NENACO through an equity infusion. In 2012, the company was reorganized and rebranded as 2GO Group Inc. with its brands SuperFerry, SuperCat, and Cebu Ferries merged with Negros Navigation to form 2GO Travel. In 2016, SM Investments Corporation (SMIC) and Chelsea Logistics and Infrastructure Holdings Corp. (owned by Dennis Uy) jointly acquired a major stake in 2GO Group Inc. In 2021, Chelsea Logistics sold its shares to SMIC, making 2GO a full subsidiary of SM Investments Corporation.

=== October === October 10, 2008: Singapore First Asian country to slip into a recession since the credit crisis began. Singapore's export-dependent economy shrank an annualized 6.3% in the third quarter after a revised 5.7% contraction in the second quarter; its first recession since 2002. Growth has faltered in Singapore as a result of less demand for exports, a reduction in tourism, and the end of the real-estate boom. Singapore's manufacturing sector had declined 4.9% in the previous quarter.

The acquisitions of Argenta and BioFocus in 2014 allowed Charles River to establish itself as a full-service, early-stage contract research organization with integrated in vitro and in vivo capabilities from target discovery through pre-clinical development. In July 2015, the company announced it would acquire Celsis International for $212 million. In 2016, the company announced it was set to acquire WIL Research for approximately $585 million in cash and Blue Stream Laboratories. In August 2017, the business announced it would acquire Brains On-Line. In January 2018, the company announced it would acquire KWS BioTest for up to £18 million ($24.4 million). In February of the same year, Charles River announced it would acquire MPI Research for approximately $800 million in cash. The transaction was completed on April 3, 2018. In February 2019, the company announced it would acquire Citoxlab for €448 million in cash (approximately $500 million), including the former acquisitions of the French company, AccelLAB, Atlanbio and Solvo Biotechnology. The transaction was completed on April 29. In December of the same year the business announced it would acquire HemaCare for approximately $380 million in cash. In August 2020, the company announced it would acquire Cellero for $38 million in cash. In January 2021, the company announced it would acquire Distributed Bio, Inc., an antibody discovery business. In February 2021, Charles River announced it would acquire Cognate BioServices, Inc. for $875 million.

In carbohydrate anabolism, simple organic acids can be converted into monosaccharides such as glucose and then used to assemble polysaccharides such as starch. The generation of glucose from compounds like pyruvate, lactate, glycerol, glycerate 3-phosphate and amino acids is called gluconeogenesis. Gluconeogenesis converts pyruvate to glucose-6-phosphate through a series of intermediates, many of which are shared with glycolysis. However, this pathway is not simply glycolysis run in reverse, as several steps are catalyzed by non-glycolytic enzymes. This is important as it allows the formation and breakdown of glucose to be regulated separately, and prevents both pathways from running simultaneously in a futile cycle. Although fat is a common way of storing energy, in vertebrates such as humans the fatty acids in these stores cannot be converted to glucose through gluconeogenesis as these organisms cannot convert acetyl-CoA into pyruvate; plants do, but animals do not, have the necessary enzymatic machinery. As a result, after long-term starvation, vertebrates need to produce ketone bodies from fatty acids to replace glucose in tissues such as the brain that cannot metabolize fatty acids. In other organisms such as plants and bacteria, this metabolic problem is solved using the glyoxylate cycle, which bypasses the decarboxylation step in the citric acid cycle and allows the transformation of acetyl-CoA to oxaloacetate, where it can be used for the production of glucose.

Sources: en.wikipedia.org

Notes from published material

Scottish scientist James W. Black developed propranolol in the 1960s. It was the first beta blocker effectively used in the treatment of coronary artery disease and hypertension. Black received the Nobel Prize in Physiology or Medicine in 1988 for this discovery. Propranolol is on the WHO Model list of essential medicines. Newer, more cardio-selective beta blockers (such as bisoprolol, nebivolol, carvedilol, or metoprolol) are used preferentially in the treatment of hypertension.

After hours of negotiations with President Trump and Speaker Johnson, all but Fitzpatrick flipped their votes to advance the rule. Starting at 4:52 a.m., House minority leader Hakeem Jeffries delivered a lengthy speech using the "magic minute" to delay the passage of the bill, eventually breaking the 8 hour and 32 minute record set by Kevin McCarthy in 2021. On July 3, the House of Representatives passed the Senate version of the OBBBA in a final mostly party-line vote of 218–214. Republican moderate Brian Fitzpatrick and fiscal conservative Thomas Massie, along with all Democrats, voted against the bill. On July 4, President Trump signed the bill into law at a ceremony at the White House.

=== Journalist spying scandal === In October 2022, Forbes reported that a team at ByteDance planned to surveil certain US citizens for undisclosed reasons. TikTok said that the tracking method suggested by the report would not be feasible because precise GPS information is not collected by the platform. In December 2022, ByteDance confirmed after internal investigation that the data of two journalists and their close contacts had been accessed by its employees from China and the United States. It was intended to uncover sources of leaks who might have met with the journalists from Forbes and the Financial Times. The data included IP addresses, which can be used to approximate a user's location. ByteDance stated that it fired four employees in response. The incident is being investigated by the US Department of Justice and FBI. The US Attorney for the Eastern District of Virginia reportedly subpoenaed information from ByteDance regarding its surveillance of journalists on TikTok. In December 2023, the United States House Select Committee on Strategic Competition between the United States and the Chinese Communist Party inquired the FBI about the status of the case.

Sources: en.wikipedia.org

Further detail

=== Protection === The lungs possess several characteristics which protect against infection. The respiratory tract is lined by respiratory epithelium or respiratory mucosa, with hair-like projections called cilia that beat rhythmically and carry mucus. This mucociliary clearance is an important defence system against air-borne infection. The dust particles and bacteria in the inhaled air are caught in the mucosal surface of the airways, and are moved up towards the pharynx by the rhythmic upward beating action of the cilia. The lining of the lung also secretes immunoglobulin A which protects against respiratory infections; goblet cells secrete mucus which also contains several antimicrobial compounds such as defensins, antiproteases, and antioxidants. The size of the respiratory tract and the flow of air also protect the lungs from larger particles. Smaller particles deposit in the mouth and behind the mouth in the oropharynx, and larger particles are trapped in nasal hair after inhalation.

The creatine phosphate shuttle is an intracellular energy shuttle which facilitates transport of high energy phosphate from muscle cell mitochondria to myofibrils. This is part of phosphocreatine metabolism. In mitochondria, Adenosine triphosphate (ATP) levels are very high as a result of glycolysis, TCA cycle, oxidative phosphorylation processes, whereas creatine phosphate levels are low. This makes conversion of creatine to phosphocreatine a highly favored reaction. Phosphocreatine is a very-high-energy compound. It then diffuses from mitochondria to myofibrils. In myofibrils, during exercise (contraction) ADP levels are very high, which favors resynthesis of ATP. Thus, phosphocreatine breaks down to creatine, giving its inorganic phosphate for ATP formation. This is done by the enzyme creatine phosphokinase which transduces energy from the transport molecule of phosphocreatine to the useful molecule for contraction demands, ATP, an action performed by ATPase in the myofibril. The resulting creatine product acts as a signal molecule indicating myofibril contraction and diffuses in the opposite direction of phosphocreatine, back towards the mitochondrial intermembrane space where it can be rephosphorylated by creatine phosphokinase. At the onset of exercise phosphocreatine is broken down to provide ATP for muscle contraction. ATP hydrolysis results in products of ADP and inorganic phosphate. The inorganic phosphate will be transported into the mitochondrial matrix, while the free creatine passes through the outer membrane where it will be resynthesized into PCr.

The acyl carrier protein (ACP), aryl carrier protein (ArCP), and the peptidyl carrier protein (PCP) are a family of protein cofactors that participate in fatty acid (acyl), polyketide (acyl and aryl), and nonribosomal peptide (peptidyl) biosynthesis. The growing molecule is bound to the A(r)/PCP via a thioester derived from the distal thiol of a 4'-phosphopantetheine (PPant) moiety. A(r)/PCPs are found in bacteria and eukaryotes (including humans) alike. The E. coli version (EcacpP) is the best studied. In E. coli, the ACP is one of the most abundant cytosolic proteins at 0.25% of the total soluble protein (by molecule count). It is small, very acidic, and very soluble. EcacpP works as a cofactor in the synthesis of both long and short chain fatty acids in the bacterium. It interacts with fatty acid synthase proteins that "flips" the growing fatty acid chain out of the ACP's internal cavity and modifies it. This kind of setup where the ACP exists as a free-floating protein is called Type II. An alternative is the Type I system, where a large protein contains several synthase domains as well as its own ACP domain. The ACP domain is pass around by the synthase domains to build a molecule. Polyketide synthases and nonribosomal peptide synthetases interact with their carrier proteins in a similar way. There is a similar distinction in how they are organized into type I and type II. Plant ACPs participate in the biosynthesis of fatty acids, exploited by humans in the form of vegetable oils.

Sources: en.wikipedia.org

Frequently asked questions

How is Selank administered in studies?

Intranasal administration predominates in both animal and human research because it avoids hepatic first-pass metabolism. Injectable and intraperitoneal routes appear in animal work mainly for comparison.

What endpoints do researchers measure?

Behavioral endpoints include time spent in open arms of the elevated plus maze and avoidance latencies. Biochemical endpoints include BDNF concentration, cytokine levels, and monoamine metabolite ratios in brain tissue.

What are the main evidence gaps?

Most published studies are small, originate from a limited number of laboratories, and lack independent replication. Dose-response relationships, measured brain exposure, and long-term outcomes are not well characterized.

How is purity determined?

Purity is usually reported as an HPLC area percentage, most often measured at 214 nm. Identity is confirmed separately by mass spectrometry. A certificate of analysis should state both the method and the observed value.

Network